Lista de obras - M Jenner - Dominio Público Uruguay

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

artículo científico publicado en 2010

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

artículo científico publicado en 2016

Advances in oral therapy for multiple myeloma.

artículo científico publicado en 2006

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

artículo científico publicado en 2008

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

article

Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants

article published in the Proceedings of the National Academy of Sciences of the United States of America

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

artículo científico publicado en 2015

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

artículo científico publicado en 2006

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

scientific article published on 01 May 2007

Liposomal cytarabine in cerebrospinal fluid.

artículo científico publicado en 2008

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

artículo científico publicado en 2008

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

artículo científico publicado en 2017

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

artículo científico publicado en 2017

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

artículo científico publicado en 2016

Sub-clonal copy number is associated with prognosis in multiple myeloma

artículo científico publicado en 2018

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.

artículo científico publicado en 2008

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

artículo científico publicado en 2010

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone

artículo científico publicado en 2007

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a

artículo científico publicado en 2006

Updates to the guidelines for the diagnosis and management of multiple myeloma

artículo científico publicado en 2014

Lista de obras de M Jenner

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Advances in oral therapy for multiple myeloma.

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma

Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic variants

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

Liposomal cytarabine in cerebrospinal fluid.

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

Sub-clonal copy number is associated with prognosis in multiple myeloma

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone

The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a

Updates to the guidelines for the diagnosis and management of multiple myeloma